Clinical Trials Logo
  1. Home
  2. Pituitary Tumor
  3. NCT03309319

A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas

Pituitary Tumor Clinical Trial

Official title:
A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas

Clinical Trial Summary

Growth hormone secreting pituitary adenomas(GHomas) produce excessive GH, stimulating excessive insulin like growth factor 1(IGF-1) synthesis in the liver, thus causing multiple systemic complications. The life expectancy of patients with untreated GHomas is shortened by ten years. The treatment goal of GHomas is to shrink the tumor volume and normalize GH and IGF-1. Under current treatment, only 50-70% of patients get remission. Rosiglitazone is a widely used oral antidiabetic medicine. The investigator's preliminary data showed that rosiglitazone decreased the synthesis of GH and IGF-1 in rat pituitary tumor cells GH3 and hepatocytes respectively. The investigator plan to investigate the efficacy of rosiglitazone in the treatment of patients with GHomas who have not been alleviated by other therapies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03309319
Study type Interventional
Source Huashan Hospital
Contact
Status Recruiting
Phase N/A
Start date October 16, 2016
Completion date December 31, 2018
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04529356 - The TMS Treatment for Postoperative Headache in GH Tumor N/A
Completed NCT03363126 - Visual Outcome After Transsphenoidal Surgery for Pituitary Macroadenoma N/A
Completed NCT04212793 - Detection of PitNET Tissue During TSS Using Bevacizumab-800CW Phase 1
Terminated NCT04106531 - Validation of a Quality of Life Metric "Prolac-10"
Recruiting NCT03719781 - Postoperative Cognitive Dysfunction in Patients Undergoing Pituitary Removal Surgery
Recruiting NCT01556230 - Prospective Study of Clinically Nonfunctioning Pituitary Adenomas
Recruiting NCT03132259 - Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Phase 4
Recruiting NCT01368133 - The Observational Study of Growth Hormone-secreting Pituitary Tumors N/A
Withdrawn NCT04863339 - Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery Phase 2
Terminated NCT00646308 - Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas N/A
Recruiting NCT00852501 - Characterization of Receptors in Non-functioning Pituitary Macroadenomas Phase 4
Completed NCT03465423 - Comparison of Propofol Requirement Between Patients With Pituitary Somatotroph Tumor and With Nonfunctioning Pituitary Tumor in Transsphenoidal Pituitary Surgery Under Total Intravenous Anesthesia
Recruiting NCT03474601 - Seoul National University Pituitary Disease Cohort Study
Recruiting NCT05139277 - Evaluation of the CONVIVO System N/A
Active, not recruiting NCT03636568 - Hyponatremia Study (Delayed Hyponatremia After Pituitary Surgery) N/A
Completed NCT02813044 - Effects of Total Intravenous Anesthesia With Propofol-remifentanil Versus Inhalational Anesthesia With Sevoflurane on Quality of Recovery in Patients Undergoing Transsphenoidal Surgery for Pituitary Tumor N/A
Recruiting NCT03973450 - Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia
Active, not recruiting NCT04042753 - Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors Phase 2
Recruiting NCT04018963 - The Impact of Endoscopic Pituitary Surgery on Nasal Function
Not yet recruiting NCT04938401 - Construction and Application of a Risk Prediction Model Forepistaxis After Pituitary Tumor Resection